Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management is a research paper published in JAMA (2022). On theSindex it has a DataRank of 1.0. It has been cited 21 times, with 21 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0.575
From 19 citing papers with measurable signal
National Institutes of Health
Grant: 3UM1AI106701-12S1
AIDS Clinical Trial Group Laboratory Center
National Institutes of Health
Grant: 2UM1AI069412-08
Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)
National Institutes of Health
Grant: 1P30AI060354-01
Harvard Medical School Center for AIDS Research
FWCI
1.93
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords